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Abstract
Lamins are crucial proteins for nuclear functionality. Here, we
provide new evidence showing that increased lamin B1 levels
contribute to the pathophysiology of Huntington’s disease (HD), a
CAG repeat-associated neurodegenerative disorder. Through fluo-
rescence-activated nuclear suspension imaging, we show that
nucleus from striatal medium-sized spiny and CA1 hippocampal
neurons display increased lamin B1 levels, in correlation with altered
nuclear morphology and nucleocytoplasmic transport disruption.
Moreover, ChIP-sequencing analysis shows an alteration of lamin-
associated chromatin domains in hippocampal nuclei, accompanied
by changes in chromatin accessibility and transcriptional dysregula-
tion. Supporting lamin B1 alterations as a causal role in mutant
huntingtin-mediated neurodegeneration, pharmacological normal-
ization of lamin B1 levels in the hippocampus of the R6/1 mouse
model of HD by betulinic acid administration restored nuclear home-
ostasis and prevented motor and cognitive dysfunction. Collectively,
our work points increased lamin B1 levels as a new pathogenic
mechanism in HD and provides a novel target for its intervention.
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Introduction
Lamins are type V intermediate filaments that together with lamin-
binding proteins are embedded into the inner nuclear membrane
and constitute the nuclear lamina (de Leeuw et al, 2018). This
family of proteins is classified into two subgroups: A-type lamins
(lamins A and C), encoded by the LMNA gene, and B-type lamins
(lamins B1 and B2), encoded by LMNB1 and LMNB2 genes, respec-
tively (de Leeuw et al, 2018). It was long thought that their only
function was to provide a structural support to the nuclear envelope
membrane, but evidence indicates that they are involved in a wide
variety of cell functions and processes, including DNA replication,
transcription, chromatin organization, and nucleus–cytoplasm inter-
action (Hozak et al, 1995). While lamins A and C are expressed
exclusively in differentiated cells, lamin B is present in almost all
cell types independently of their differentiation state (Verstraeten
et al, 2007). This suggests that B-type lamins are essential for the
survival of mammalian cells (Harborth et al, 2001).
Alterations in lamins content or structure lead to a particular type
of nuclear envelopathies called laminopathies (Schreiber &
Kennedy, 2013). While many laminopathies are associated with
mutations in LMNA gene (Schreiber & Kennedy, 2013), only two
have been associated with alterations in lamin B: the autosomal
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dominant leukodystrophy (Padiath, 2019) and the acquired partial
lipodystrophy (Hegele et al, 2006) caused by LMNB1 and LMNB2
mutations, respectively. Interestingly, in the last few years, lamin B
alterations have also been found in neurodegenerative disorders
such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) (Liu
et al, 2012; Frost, 2016). Strikingly, two cellular functions in which
lamin B plays a critical role, RNA nuclear exportation (Gasset-Rosa
et al, 2017) and nuclear pore complex organization (Grima et al,
2017), are altered in Huntington’s disease (HD), an autosomal domi-
nant neurodegenerative disorder caused by an inherited CAG repeat
expansion in the exon 1 of the huntingtin (htt) gene (HDCRG,
1993). This mutation results in the lengthening of the polyglutamine
chain at the amino terminus of the huntingtin (Htt) protein inducing
self-association and aggregation. Consequently, mutant Htt (mHtt)
loses its biological functions and becomes toxic (Ross & Poirier,
2004). In HD, medium-sized spiny neurons (MSNs), the GABAergic
output projection neurons that account for the vast majority
(90–95%) of all striatal neurons, are mainly affected. Although
motor symptoms are the most prominent, psychiatric alterations
and cognitive decline appear first in HD patients and become more
evident as the disease progresses. Cognitive deficits are related to
the dysfunction of the corticostriatal pathway and the hippocampus
and, together with motor deficits, have been replicated in most HD
mouse models (Puigdellı́vol et al, 2016).
Molecular mechanisms leading to neuronal dysfunction in HD
remain to be elucidated. Previous results from our laboratory
suggested that decreased levels of the pro-apoptotic kinase PKCδ
would lead to an aberrant accumulation of lamin B (Rue et al, 2014)
which, in turn, could have a significant influence in the nuclear
lamina structure and function (Lin & Fu, 2009; Ferrera et al, 2014).
Therefore, here we sought to deeply characterize the impact of
lamin alterations in HD brain at physiological (studying nuclear
lamina morphology and nucleocytoplasmic transport), transcrip-
tomic (by generating RNA-sequencing (RNA-seq) data), and epige-
netic (analyzing lamin chromatin binding and chromatin
accessibility) levels by using the R6/1 transgenic mouse model of
HD and human post-mortem brain samples.
Results
Lamin B levels are increased in a region-specific manner in
HD brain
Lamin B1, lamin B2, and lamin A/C protein levels were analyzed in
the striatum, cortex, and hippocampus of wild-type and R6/1 mice,
a transgenic mouse model of HD overexpressing the exon 1 of the
human mHtt (Mangiarini et al, 1996), at different ages. Western blot
analysis revealed an increase in lamin B1 (Fig 1A) and lamin B2
(Fig 1B) levels in all three regions from early disease stages in R6/1
mice, whereas lamin A/C protein levels remained unchanged until
30 weeks of age in the striatum and hippocampus (Fig EV1). Since
the most important alterations were found in lamin B isoforms, we
investigated whether such an increase was reproducible in the brain
of HD patients. Western blot analysis revealed that lamin B1 levels
were significantly higher, in comparison with levels in non-affected
individuals, in the putamen of HD patients at Vonsattel (VS) grade
III–grade IV, and in the frontal cortex of HD patients at grade
I–grade II and grade III–grade IV (Fig EV2A). Unexpectedly, no
significant changes were found within the hippocampus of HD
patients at any disease stage. On the other hand, lamin B2 protein
levels were only increased in the frontal cortex of HD patients (Fig
EV2B). Consequently, only lamin B1 levels are consistently affected
in the brain of R6/1 mice and HD patients.
Previous studies have shown lamin alterations in the nucleus of
aged human fibroblasts (Freund et al, 2012) and keratinocytes
(Dreesen et al, 2013). In order to discard that our observations were
due merely to the aging process itself, we analyzed the correlation
between lamin B1 levels and age in human samples from the puta-
men, cortex, and hippocampus. We observed no correlation between
age and lamin B1 levels in any of the brain regions analyzed
(Appendix Fig S1A–C). In addition, the distribution of ages showed
that control and HD samples were age-matched (Appendix Fig S1D).
Thus, our results indicate that alterations in lamin B1 levels are
occurring because of the HD pathology itself. In contrast to other
studies showing that some altered mechanisms, such as transcrip-
tomic dysregulation, are dependent on the CAG repeat length (Lang-
felder et al, 2016), we did not observe a correlation between the
number of CAG repeats and lamin B1 protein levels in the putamen,
hippocampus, and cortex of HD patients (Appendix Fig S2). Thus,
lamin B1 alteration is dependent on the pathological stage rather than
on the original number of inherited CAGs.
In an attempt to investigate the molecular mechanisms leading
to the increase in lamin B1 levels, and considering our previous
results showing a possible link between decreased PKCδ and
increased lamin B levels in HD brain (Rue et al, 2014), we
knocked down PKCδ in striatal cells expressing mHtt. Once the
efficiency of PKCδ siRNA was analyzed by Western blot (Fig
EV3A), wild-type striatal cells (STHdhQ7/Q7) were co-transfected
with exon 1 encoded N-terminal Htt with 94 glutamines fused to
cyan-fluorescent protein (CFP) (N-mHtt-CFP) and a PKCδ siRNA
or a scramble siRNA as a control. Lamin B1 levels were analyzed
by immunocytochemistry 24 h after transfection. We observed that
lamin B1 levels were increased in the nucleus of striatal cells
transfected with N-mHtt-CFP in the PKCδ siRNA condition as
compared to those cells transfected with N-mHtt-CFP plus scram-
ble siRNA (Fig EV3B and C). Moreover, we analyzed PKCδ levels
in striatal and hippocampal samples from the same R6/1 mice used
to analyze lamin B1 levels, and we observed a significant correla-
tion between the reduction in PKCδ and the increase in lamin B1
levels in the striatum, but not in the hippocampus (Fig EV3D).
Therefore, our results suggest that decreased PKCδ levels could be
involved in the accumulation of lamin B1 in R6/1 mouse striatum,
but not in the hippocampus.
Lamin B1-increased levels are mainly localized in neurons
To address the cell type specificity of the lamin B1 increase, we
performed NeuN and lamin B1 co-immunostaining (with or without
GFAP), in brain sections obtained from 30-week-old R6/1 mice and
from HD patients at different stages of the disease, and their corre-
sponding controls. Observation of confocal z-stacks images from the
striatum of R6/1 mice showed a strong increase in lamin B1 signal,
which was more prominent in NeuN-positive nuclei (Fig 2A). These
nuclei showed nuclear lamina invaginations and lamin B1 delocal-
ization within the nucleoplasm, resulting in altered morphological
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parameters as compared to wild-type mice nuclei (Fig EV4).
Furthermore, and similarly to what we observed for GFAP-positive
cells, nucleus from striatal oligodendrocytes did not show alter-
ations in lamin B1 levels nor in morphology (Appendix Fig S3). In
line with that, neurons from the putamen of HD patients displayed
lamin B1 signal delocalization within the nucleus, while lamin B1
was not altered in the nuclei of GFAP-positive cells (Fig 2B and C).
In the hippocampus of R6/1 mice, the dentate gyrus (DG) and the
Cornu ammonis 1 (CA1) regions presented the highest increase in
lamin B1 signal (Fig 3A). Moreover, CA1 neuronal nuclei displayed
morphological alterations and lamin B1 protein delocalization from
the nuclear periphery, as observed in 3D reconstructions of z-stack
A
B
Figure 1. Lamin B1 and lamin B2 are differentially increased in R6/1 mouse brain.
Lamin B1 and lamin B2 were analyzed by Western blot in R6/1 mice at different stages of the disease progression (w: weeks) and their corresponding controls (WT: wild-
type littermates).
A Quantification and representative immunoblots of lamin B1 in the striatum (8w, 12w, and 20w: N = 6 for both genotypes; 30w: N = 4 and 5 for WT and R6/1 mice,
respectively), hippocampus (8w: N = 8 and 6 for WT and R6/1 mice, respectively; 12w: N = 7 and 6 for WT and R6/1 mice, respectively; 20w: N = 5 and 6 for WT and
R6/1 mice, respectively; 30w: N = 8 and 5 for WT and R6/1 mice, respectively), and cortex (8w: N = 5 and 4 for WT and R6/1 mice, respectively; 12w and 20w: N = 6
for both genotypes; 30w: N = 6 and 5 for WT and R6/1 mice, respectively).
B Quantification and representative immunoblots of lamin B2 in the striatum (8w, 12w, and 20w: N = 6 for both genotypes, 30w: N = 5 for both genotypes),
hippocampus (8w: N = 8 and 6 for WT and R6/1 mice, respectively; 12w: N = 6 and 7 for WT and R6/1 mice, respectively; 20w: N = 5 for both genotypes; 30w: N = 8
and 5 for WT and R6/1 mice, respectively), and cortex (8w and 12w: N = 6 for both genotypes; 20w: N = 5 for both genotypes; 30w: N = 8 and 5 for WT and R6/1
mice, respectively).
Data information: Data are expressed as a percentage of controls. Each point corresponds to the value from an individual sample. Bars represent the mean  SEM.
*P < 0.05, **P < 0.01, and ***P < 0.001 as compared with WT mice (two-tailed unpaired Student’s t-test). Tubulin was used as loading control. Exact P values are
reported in Appendix Table S3.
Source data are available online for this figure.
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lamin B1 images (Fig 3B). Interestingly, at early disease stages
(12 weeks), these changes appeared to be restricted to the CA1
region (Appendix Fig S4). Strikingly, these morphological alterations
seemed to be independent to the presence of mHtt inclusions as
indicated by the EM48 immunostaining in the R6/1 mice striatal and
CA1 hippocampal nuclei (Appendix Fig S5). Overall, these results
indicated a cell-type-specific increase in lamin B1 levels in response
to mHtt in co-occurrence with lamin B1 delocalization and nuclear
lamina morphological alterations that seemed to be independent of
the presence of mHtt inclusions.
Cell type-specific nuclear morphology alterations correlate with
increased lamin B1 levels
To further confirm our observations indicating increased lamin B1
protein levels and nuclear morphology alteration in specific cell
populations, fluorescence-activated nuclear suspension imaging
(FANSI) method was developed by combining nuclear isolation
from brain tissue with immunostaining (Benito et al, 2015) and the
recently developed imaging flow cytometry (Barteneva & Vorobjev,
2016), allowing the acquisition of individual nucleus images. By
combining antibodies against Ctip2 and NeuN, we discerned
between MSNs (Ctip2+/NeuN+), which represent around 90% of
total striatal neurons (Kemp & Powell, 1971), striatal interneurons
(Ctip2−/NeuN+), and glial cells (Ctip2−/NeuN−; Appendix Fig S6A).
As shown in Fig 4, we detected an increase in lamin B1 levels and
altered nuclear morphology in 30-week-old R6/1 MSNs (Fig 4A), but
not in striatal interneurons (Fig 4B) nor in glial cells (Appendix Fig
S7), supporting our previous observations (see Fig 2 and
Appendix Fig S3). Nuclear area and total number of counted nuclei
were not altered in comparison with wild-type mice, in agreement
with the lack of neuronal death observed in R6/1 mouse brain (Fran-
celle et al, 2014). In addition, we confirmed that these alterations
were independent to the presence of mHtt inclusions. As shown in
Fig 4C, alterations in lamin B1 levels and nuclear morphology simi-
larly occur in striatal neuronal nuclei with or without mHtt inclu-
sions. In the putamen of HD patients, the number of Ctip2+/NeuN+
nuclei examined by FANSI was extremely low (10 neuronal nuclei
in average for each sample) what made it difficult to reach a conclu-
sion (Appendix Fig S8A). Therefore, we decided to analyze lamin
B1 intensity and circularity by immunohistochemistry. We observed
that lamin B1 intensity was increased only in the nuclei of MSNs
from VS III-IV patients, in correlation with altered nuclear morphol-
ogy (Fig 4D). In addition, and accordingly to results obtained in R6/
1 mice striatum, FANSI analysis showed no alterations in the nuclei
of striatal glial cells from HD patients in comparison with control
individuals (Appendix Fig S8B). In the hippocampus, to distinguish
between DG and CA1 neuronal nuclei, we used antibodies against
Ctip2 and Prox1 (Appendix Fig S6B). In 30-week-old R6/1 mouse
hippocampus, we detected increased lamin B1 levels only in CA1
neuronal nuclei (Ctip2+/ Prox1−) in concomitance with morphologi-
cal alterations, while neuronal nuclei from DG (Ctip2+/ Prox1+)
were relatively spared. Furthermore, no alterations were found in
the total number of nuclei or in nuclear area (Fig 4E). Altogether,
these results suggest that increased lamin B1 levels contribute to
nuclear morphology alterations in specific neuronal populations in
HD brain. To test this, striatal primary cultures were transfected
with a plasmid expressing lamin B1-mApple or mApple as a control,
and nuclear morphology was examined 24 h after transfection by
confocal microscopy. We observed that lamin B1 overexpression in
cultured striatal neurons induced a dramatic alteration of nuclear
morphology (Fig 5A and B) and chromatin condensation (Fig 5B).
Increased lamin B1 levels correlate with alterations in nuclear
permeability in MSNs and CA1 hippocampal neurons from
R6/1 mice
Our previous results showed that striatal MSNs and CA1 hippocampal
neuronal nuclei are preferentially affected by altered lamin B1 levels.
Since alterations in nuclear architecture lead to changes in nuclear
permeability (Hatch & Hetzer, 2014), we wondered whether increased
lamin B1 levels could contribute to nuclear transport abnormalities.
To address this hypothesis, we performed fluorescence recovery after
photobleaching (FRAP) experiments in isolated 30-week-old wild-
type and R6/1 mice neuronal nuclei by using 20 kDa FITC-dextran
(Fig 6A). We detected that half-time of recovery (t1/2) in R6/1 striatal
MSNs (Fig 6B) and CA1 hippocampal (Fig 6C), but not DG (Fig 6D),
nuclei was slower than in wild-type mice. Bleaching percentage and
maximum fluorescence recovered (plateau) did not differ between
genotypes (Appendix Fig S9A and B). As a validation, FRAP was
performed in the background, where any of the analyzed parameters
was found altered (Appendix Fig S9C). Altogether, our results show
an alteration in the passive diffusion of dextran into neuronal nuclei
containing greater lamin B1 protein levels, suggesting that nucleocy-
toplasmic passive transport abnormalities are linked to lamin B1
alterations in a cell type-dependent manner.
Lamin B1 chromatin binding is impaired in R6/1
mice hippocampus
Lamin B1 is classically associated with large heterochromatin
domains called lamin-associated domains (LADs), characterized by
▸Figure 2. Lamin B1 distribution in the striatum of R6/1 mouse and in the putamen of HD patients.A Mouse brain tissue was processed for immunohistochemistry by combining anti-lamin B1 (red) and anti-NeuN (green) antibodies. Representative images (maximal Z-
projections) showing the distribution of lamin B1 in the striatum of 30-week-old wild-type (WT) and R6/1 mice. Yellow arrowheads show co-localization between
lamin B1 and NeuN, and white arrowheads show NeuN negative lamin B1-positive nuclei. Scale bar 50 and 25 µm for low and high magnification, respectively.
B Lamin B1 distribution in human putamen was analyzed by immunohistochemistry. Antibody against lamin B1 (red) was combined with DAPI Fluoromount-G (blue)
to label nuclei. Representative images show the distribution of lamin B1 in the putamen of non-affected individuals (CTL) and HD patients at different stages of the
disease (VS II-IV: Vonsattel grades). Yellow and white arrowheads indicate MSNs and glial cells, respectively. Scale bar 50 and 20 µm for low and high magnification,
respectively.
C The distribution of lamin B1 in the putamen of HD patients was analyzed by immunohistochemistry. Anti-lamin B1 antibody (red) was combined with anti-GFAP
antibody (green), and nuclei were labeled with DAPI Fluoromount-G (blue). Representative images show the distribution of lamin B1 at Vonsattel grade III. Yellow
arrowheads indicate MSNs, and white arrowheads indicate GFAP-positive cells. Scale bar 10 µm.
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low gene expression levels (Belmont et al, 1993). Recently,
however, LADs have been linked to actively transcribed euchro-
matic regions (Pascual-Reguant et al, 2018). Therefore, we set out to
study whether increased lamin B1 levels in HD brain could alter
their chromatin-binding landscape. For that, we generated lamin B1
chromatin immunoprecipitation and sequencing (ChIP-seq) data in
30-week-old wild-type and R6/1 mice hippocampus (age and region
showing the highest increase in lamin B1 levels). We immunopre-
cipitated lamin B1 and verified that both heterochromatin and
euchromatin fractions were efficiently sonicated (Appendix Fig
S10A and B). This indicated that all lamin B1-bound regions should
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A
B
Figure 3. Lamin B1 distribution in the hippocampus of R6/1 mouse.
Hippocampal sections from 30-week-old wild-type (WT) and R6/1 mice were labeled with anti-lamin B1 antibody (red), and anti-GFAP antibody (green) and nuclei were
labeled with DAPI Fluoromount-G (blue).
A Representative images showing the distribution of lamin B1. On the left, images showing maximal Z-projection. Scale bar 150 µm. Small images correspond to CA1
and DG magnified images showing independent DAPI, GFAP, and lamin B1 channels, and merge, of representative confocal Z-stack images. Scale bar 50 µm.
B Left, representative images showing the distribution of lamin B1 in the nuclei of CA-1 hippocampal neurons from WT and R6/1 mice along different Z-axis planes (1-
6). On the right, a 3D reconstruction of the Z-stack confocal images generated using ImageJ. Scale bar 20 µm.
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calling tool (Lund et al, 2014) and identified 145 and 166 LADs in
wild-type and R6/1 mice hippocampus, respectively (Fig 7A and B),
showing a genotype-dependent component in our lamin B1 ChIP-
seq data (Appendix Fig S10C). These numbers were consistently
found in triplicates of each experiment (Appendix Fig S10D and E),
and the regions overlapped with LADs previously identified in
neural progenitor cells using DamID (Peric-Hupkes et al, 2010)
(Appendix Fig S10F). Our LADs were depleted of H3K9ac and CTCF
and highly enriched in H3K9me3, which are major features of
canonical gene-silencing LADs (Appendix Fig S10G). We observed a
lower average size and lamin B1 binding in R6/1 mice-specific LADs
(Fig 7A and B). Interestingly, while most of the regions identified by
EDD were common between wild-type and R6/1 mice, a small
subset of them were specifically identified in one of the genotypes
(Fig 7C). We found regions specific from R6/1 mouse, but they were
equally enriched in lamin B1 in both genotypes, suggesting an arte-
factual origin from the EDD tool. For wild-type mice-specific
regions, however, we observed a clear reduction in lamin B1 bind-
ing in R6/1 mice (Fig 7C). Genes located within common LADs
between wild-type and R6/1 mice were enriched in terms mostly
related to “olfactory sensory perception” and “keratinization” (Fig 7
D). However, genes within wild-type mice exclusively identified
regions showed a strong differential functional signature, being
mostly enriched in genes related to “nucleosome assembly” (Fig 7
D). In line with this, nuclear fractionation clearly showed a reduc-
tion in the proportion of lamin B1 bound to chromatin, with a paral-
lel accumulation of lamin B1 protein within the nucleoplasm
(Fig 7E). Altogether, these results suggest that alterations in lamin
B1 protein levels and localization in R6/1 mice hippocampus lead to
changes in the genome-wide map of LADs, which ultimately could
affect the expression and accessibility of certain genes.
Chromatin accessibility, gene transcription, and LAD organization
in R6/1 mice hippocampus
To study the impact of lamin B1 chromatin-binding alterations in
chromatin state and gene expression, we analyzed chromatin acces-
sibility and gene expression levels by generating assay for trans-
posase-accessible chromatin and parallel sequencing (ATAC-seq;
Fig 8A and Appendix Fig S11A) and RNA-seq data using 30-week-
old R6/1 mice hippocampus. We identified a similar number of
ATAC-seq peaks in wild-type and R6/1 mice hippocampus
(260,284  4,559 and 254,672  9,030, respectively) by using three
independent biological replicates, indicating no massive changes in
chromatin accessibility between genotypes. Differential peak acces-
sibility analysis showed a high genotype-dependent component in
our ATAC-seq data (Appendix Fig S11B), and identified 1,304 and
803 regions with gained or lost accessibility, respectively, in R6/1
mice hippocampus (adjusted P-value < 0.05). These regions were
predominantly distal regulatory elements localized at intronic and
intergenic regions (Appendix Fig S11D). Motif analysis identified
EGR1/2 and NEUROD2 as centrally transcription factors enriched in
each set of differential accessible peaks (Appendix Fig S11C). To
gain insight into functional relevance of these changes, differential
accessible regions were annotated to the closest transcription start
site (TSS). Genes showing a loss of accessibility in R6/1 mice
displayed a clear neuronal signature, with enriched terms such as
“positive regulation of synapse” or “chemical synaptic
transmission”, while genes associated with an increase in chromatin
accessibility were mostly associated with developmental- and tran-
scriptional-related terms (Fig 8B). The transcriptome of both geno-
types (n = 9) clearly differed (as shown by PCA in Appendix Fig
S11E). We found 2,145 up-regulated and 2,280 down-regulated
genes (adjusted P-value < 0.001) in R6/1 with respect to wild-type
mice hippocampus. Gene ontology analysis of differentially
expressed genes showed high homology with the one found in our
ATAC-seq data, with a predominance of neuronal-related and tran-
scriptional-related terms for down- and up-regulated genes, respec-
tively (Appendix Fig S11F). In addition, we found a substantial
overlap with previously identified sets of altered expressed genes in
other HD mouse models (Appendix Fig S11G) (Langfelder et al,
2016; Hervas-Corpion et al, 2018). As expected, we found that only
genes showing the highest transcriptional dysregulation (adjusted P-
value < 0.001, |fold change| > 2) displayed significant changes in
chromatin accessibility at their TSS as compared with genes only fil-
tered according to their adjusted P-value (Fig 8C and Appendix Fig
S11H). However, when analyzing transcriptional changes associated
with identified differential accessible regions, a clear correlation was
observed (Fig 8D), suggesting that distal regulatory element accessi-
bility better accounts for transcriptional dysregulation in R6/1 mice
hippocampus.
When focusing on LADs reported in both genotypes, as expected,
we found a particular enrichment in genes with low transcriptional
rate (Fig 9A). However, when we analyzed LADs specifically found
in wild-type mice or common between both genotypes (Fig 7C),
minor changes were found either at transcriptional level (Fig 9B) or
in terms of chromatin accessibility (Fig 9C), indicating that loss of
lamin B1 binding in R6/1 mice hippocampal cells does not lead to a
global transcriptional induction in these regions. Additionally, we
analyzed the presence of genes differentially expressed within the
set of genes specifically found in wild-type mice LADs (lost in R6/1
mouse; see Fig 7C) or in wild-type and R6/1 mice common LADs
(Fig 9D). We found that genes differentially expressed between
wild-type and R6/1 mice were more enriched in wild-type-specific
LADs than in wild-type and R6/1 common LADs (up-regulated: 119/
1242 in wild-type-specific LADs versus 142/3654 in common LADs;
down-regulated: 110/1242 in wild-type-specific LADs versus 198/
3654 in common LADs), indicating that loss of lamin B1 chromatin
binding in R6/1 mice hippocampal cells could lead to chromatin
reorganization affecting genes within these regions. However, when
focusing on highly dysregulated genes (|fold change| > 2), this
enrichment was only observed for down-regulated genes (down-
regulated: 10/1,242 in wild-type-specific LADs versus 21/3,654 in
common LADs; up-regulated: 3/1,242 in wild-type-specific LADs
versus 9/3,654 in common LADs). Furthermore, we analyzed
whether regions with differential accessibility between wild-type
and R6/1 mice displayed changes in lamin B1 chromatin binding.
Not surprisingly, ATAC-seq regions were generally depleted of
lamin B1 occupancy (Fig 9E, left panel). However, when comparing
regions showing increased or decreased chromatin accessibility in
R6/1 mice to unchanged regions, a highest occupancy of lamin B1
was observed in the first, especially in regions with decreased acces-
sibility (Fig 9E, right panel). Interestingly, a significant decrease in
lamin B1 occupancy was observed in regions with increased accessi-
bility in R6/1 mice, suggesting that lamin B1 chromatin-binding
impairment could indeed lead to localized increase in chromatin
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◀ Figure 4. Increase in lamin B1 levels and altered nuclear morphology occur in striatal MSNs and hippocampal CA-1 neurons from R6/1 mice.Lamin B1 levels and morphology were analyzed in specific neuronal nuclei from the striatum and hippocampus of 30-week-old wild-type (WT) and R6/1 mice, and in the
putamen of HD patients by FANSI and immunohistochemistry, respectively.
A Graphs show the quantification of different parameters in mice striatal MSN nuclei (Ctip2+/NeuN+). N = 4 for both genotypes. An average of 5,000 nuclei were
analyzed for each sample. Representative images are shown. Scale bar 7 µm.
B Graphs show the quantification of different parameters in mice striatal interneurons (Ctip2-/NeuN+). N = 4 for both genotypes. An average of 5,000 nuclei were
analyzed for each sample. Representative images are shown. Scale bar 7 µm.
C Graphs show the quantification of lamin B1 intensity and circularity in 30-week-old R6/1 mouse striatal neuronal nuclei with (mHtt +) or without (mHtt −) nuclear
inclusions. N = 6. EM48 antibody was used to label mHtt inclusions. Representative images are shown. Scale bar 7 µm.
D Graphs showing lamin B1 intensity and circularity in MSN nuclei from the putamen of HD patients at different stages of the disease (VS: Vonsattel grade) and
corresponding controls (CTL: non-affected individuals). N = 6 for CTL, N = 3 for VS I-II, and N = 4 for VS III-IV. An average of 50 nuclei were examined for each
sample. Representative images (maximal Z-projections) are shown. Scale bar 7 µm.
E Graphs show the quantification of different parameters in hippocampal CA1 (Ctip2+/Prox1−) and DG (Ctip2+/Prox1+) neuronal nuclei. N = 4 for each genotype.
Representative images are shown. Scale bar 7 µm.
Data information: Each point corresponds to the value from an individual sample. Bars represent the mean  SEM. Data in (A-C) and (E) were analyzed by two-tailed
unpaired Student’s t-test. *P < 0.05, **P < 0.01, and ***P < 0.001 as compared with corresponding controls. Data in (D) were analyzed by one-way ANOVA followed by
Tukey’s post hoc test. *P < 0.05 as compared with CTL; #P < 0.05 as compared with VS I-II. Exact P values are reported in Appendix Table S3.
Source data are available online for this figure.
A
B
Figure 5. Lamin B1 overexpression in primary striatal neurons alters nuclear morphology.
Primary striatal neurons were transfected with a vector to overexpress lamin B1 (mApple-LB1) or with an empty vector (mApple-C1), and lamin B1 intensity and nuclear
circularity were examined by immunocytochemistry against lamin B1 24 h after transfection.
A Graphs show the quantification of lamin B1 intensity and circularity. N = 3. An average of 12 nuclei were examined in each culture. Data are expressed as a
percentage of controls. Bars represent the mean  SEM. *P < 0.05 and **P < 0.01 as compared to mApple-C1 control neurons (two-tailed unpaired Student’s t-test).
Exact P values are reported in Appendix Table S3.
B Representative images showing primary striatal neurons transfected with mApple-C1 or with mApple-Lamin B1, both in red. Neuronal nuclei were stained with DAPI
Fluoromount-G (blue). Lamin B1 is shown in white. Scale bar 10 µm.
Source data are available online for this figure.
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accessibility in distal regulatory elements in R6/1 mice hippocam-
pus. Overall, our results suggest that while no massive changes at
transcriptional or chromatin accessibility levels are associated with
the loss of lamin B1 heterochromatin binding, a small subset of dif-
ferentially expressed genes could be affected. Moreover, distal regu-
latory elements, and more particularly those found in regions with
gained accessibility in R6/1 mice, appear to be the more sensitive to
these lamin B1 alterations.
Treatment with betulinic acid prevents cognitive impairment in
R6/1 mice
Given the increase in lamin B1 levels and the altered nuclear
morphology and function found in R6/1 mice brain neurons, we
hypothesized that these disturbances could be possibly contributing
to motor and cognitive impairment present in HD. Betulinic acid has
been shown to transcriptionally repress LMNB1 expression (Li et al,
2013). Thus, as a clinical translational approach, we treated R6/1
mice from 8 to 20 weeks of age with 50 mg/kg betulinic acid and
analyzed behavioral, biochemical, and histopathological changes
following the timeline depicted in Fig 10A. First, we analyzed
hippocampal-dependent learning and memory by using novel object
location test (NOLT) and novel object recognition test (NORT). As
previously described (Garcia-Forn et al, 2018), vehicle-treated R6/1
mice showed impaired hippocampal-dependent learning and
memory relative to wild-type mice with a decreased percentage of
time exploring the moved (Fig 10B) or the novel (Fig 10C) objects.
Interestingly, betulinic acid-treated R6/1 mice explored similarly to
wild-type mice in the NOLT (Fig 10B) and NORT (Fig 10C), suggest-
ing that chronic administration of betulinic acid prevents cognitive
dysfunction in R6/1 mice. To assess whether learning of a corticos-
triatal motor task was also improved after treatment with betulinic
acid, we performed the accelerating rotarod task at 15 weeks of age,
when R6/1 mice show a clear difference in the performance
compared with wild-type mice (Garcia-Forn et al, 2018). Vehicle-
treated R6/1 mice displayed poor performance with a lower latency
to fall compared with control mice (Fig 10D). Importantly, betulinic
acid-treated R6/1 mice showed a significant, although partial,
improvement of their motor learning abilities.
Next, we investigated whether chronic betulinic acid treatment
affected lamin B1 protein levels in different brain regions. A reduc-
tion in lamin B1 protein levels in the cortex and hippocampus, but
not in the striatum, was detected in betulinic acid-treated compared
with vehicle-treated R6/1 mice (Fig 10E). Analysis using FANSI
revealed a normalization of lamin B1 levels in the nuclei of
hippocampal CA1 neurons in betulinic acid-treated R6/1 mice
(Fig 10F), accompanied by a partial rescue of nuclear morphology
alterations (Fig 10F). In line with these results, we observed an
amelioration of nucleocytoplasmic transport dysfunction, since half-
time of recovery after photobleaching of nuclear dextran fluores-
cence was similar in betulinic acid-treated R6/1 and vehicle-treated
wild-type mice hippocampal CA1 neuronal nuclei (Fig 10G). Impor-
tantly, as observed at 30 weeks of age, lamin B1 levels and nuclear
morphology or permeability alterations were not detected in
hippocampal DG neuronal nuclei from 20-week-old vehicle- or betu-
linic acid-treated R6/1 mice (Appendix Fig S12A and B).
Finally, we analyzed whether several hallmarks of the disease
were affected by the treatment with betulinic acid. We found that
betulinic acid did not prevent the loss in DARPP-32 levels in the
striatum of R6/1 mice, whereas it completely prevented the loss in





Figure 6. Altered nuclear permeability in R6/1 mice striatal MSNs and
hippocampal CA1 neuronal nuclei.
A Scheme showing the experimental approach followed to measure
nuclear permeability by FRAP.
B–D Nuclear permeability in 30-week-old wild-type (WT) and R6/1 mice
striatal MSNs, CA1, and DG neuronal nuclei, respectively. (B and C) N = 4
for each condition; (D) N = 5 for each condition. An average of 25 nuclei
were analyzed for each sample.
Data information: In graphs, each point corresponds to the value from an
individual sample. Bars represent the mean  SEM. *P < 0.05 as compared
with WT mice (two-tailed unpaired Student’s t-test). Exact P values are
reported in Appendix Table S3.
Source data are available online for this figure.
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we found that the number and area of mHtt aggregates in betulinic
acid-treated R6/1 mice were similar to those found in the vehicle-
treated group, both in the striatum and in the hippocampus
(Appendix Fig S12E and F), indicating that betulinic acid effects
were independent from mHtt aggregation.
Discussion
Here, we show that (I) lamin B1 protein levels are increased in
vulnerable regions of HD brain correlating with altered nuclear
morphology; (II) nucleocytoplasmic transport of small molecules is
altered in neurons showing increased lamin B1 levels in R6/1 mouse
brain; (III) in R6/1 mice hippocampus (a) lamin B1 alterations corre-
late with partial unstructuring of LADs and (b) changes in chro-
matin accessibility mostly localize at distal regulatory elements,
correlate with transcriptional dysregulation, and are partially associ-
ated with lamin B1 chromatin-binding alterations; and (IV) pharma-
cologic regulation of lamin B1 levels improves nucleocytoplasmic
transport in CA1 hippocampal neurons and ameliorates behavioral
abnormalities in R6/1 mouse.
We found that, among all lamin isoforms, lamin B1 was consis-
tently affected in the brain of both HD patients and mouse models
from early stages of the disease. B-type, but not A-type lamins, are
essential for brain development (Kim et al, 2011). In fact, none of
the laminopathies related to mutations in lamin A/C courses with
neuronal dysfunction, which could explain why lamin A/C was
unaltered in most R6/1 brain regions. Alterations in B-type lamins
have been reported in neurodegenerative disorders and aging. For
instance, and in contrast to our results, decreased lamin B levels are
found in brains from AD (Frost et al, 2016) and PD patients bearing
the LRRK2 (G2019S) mutation (Liu et al, 2012), and in aged primary
human fibroblasts (Freund et al, 2012) and keratinocytes (Dreesen
et al, 2013), being a marker of cellular senescence. Here, we show
that increased lamin B1 levels in the brain of HD patients are not
due to the aging process itself but rather to the pathogenic process.
Interestingly, autosomal dominant leukodystrophy, a laminopathy
caused by the duplication of the LMNB1 gene, courses with severe
central nervous system affectation, whose symptoms recall those of
HD (Padiath et al, 2006). These evidences prompt the idea that
increased lamin B1 levels in HD brain may be participating in the
pathophysiology of the disease.
The accumulation of lamin B1 in neuronal nuclei from HD brain
could be produced by different mechanisms such as increased tran-
scription and/or translation, or decreased degradation. Increased
transcription seems improbable since RNA-seq data generated from
hippocampus of 30-week-old R6/1 mice do not show alterations in
lamin B1 RNA levels (present results) (Hervas-Corpion et al, 2018).
In addition, although we have recently showed increased translation
in the striatum of HD mouse models and patients, the proteomic
analysis did not reveal lamin B1 as one of the proteins with
increased translation (Creus-Muncunill et al, 2019). Therefore, we
hypothesized that increased lamin B1 protein levels in HD brain
could be the result of different altered post-translational mecha-
nisms such as decreased PKCδ (Rue et al, 2014) and/or altered
autophagy-mediated lamin B1 degradation (Dou et al, 2015) and/or
increased stabilization due to overactivation of p38MAPK (Barascu
et al, 2012). Here, we show that knock-down of PKCδ in striatal
cells increases lamin B1 levels in their nuclei, and that decreased
PKCδ levels correlate with increased lamin B1 levels in the striatum,
but not in the hippocampus, of R6/1 mice. Therefore, our results
suggest that mechanisms leading to increased lamin B1 levels in HD
brain could differ in a region-dependent manner, with downregula-
tion of PKCδ playing a role in the striatum.
Immunohistochemical analysis of lamin B1 in R6/1 mouse brain
suggested that the increase occurred in striatal MSNs, hippocampal
CA1, and DG neurons. Our newly developed technique, FANSI, con-
firmed the increase in lamin B1 levels in nuclei of R6/1 striatal MSNs
and showed that in the hippocampus CA1 neurons, but not DG
neurons, were affected. Interestingly, these affected populations are
the most vulnerable neurons in HD brain and their dysfunction
participate in the motor and cognitive phenotype (Vonsattel & DiFi-
glia, 1998; Murphy et al, 2000). In the putamen of HD patients,
FANSI results indicated a significant loss of MSNs, but not of glial
cells, as previously described (Vonsattel et al, 1985). However, this
technique seemed unsuitable to analyze nuclear alterations in MSNs
◀ Figure 7. Lamin B1 chromatin binding in wild-type and R6/1 mice hippocampus.
A UCSC genome browser capture of lamin B1 ChIP-seq signal (log(LB1/Input)) and LADs discovered in wild-type (WT LAD) and R6/1 (R6/1 LADs) mice in combination
with NPC lamin B1 DamID (top). Black arrows highlight differences in identified LADs between WT and R6/1 mice ChIP-seq data. Box plots of LAD size (log10(LAD
size + 1)) and of LAD score (log10(LAD score + 1)) obtained by EDD (bottom) from WT (N = 3) and R6/1 (N = 3) lamin B1 ChIP-seq data. Hipp, hippocampus. The
bottom and top of the boxes are the first and third quartiles, and the line within represents the median. The whiskers denote the interval within 1.5 times the
interquartile range (IQR) from the median.
B Venn diagram of overlapping LADs between wild-type (WT, N = 3) and R6/1 (N = 3) mice hippocampus (top). Metaprofile of lamin B1 and input datasets mean read
density within common LADs for WT and R6/1 mice (bottom).
C UCSC genome browser capture of lamin B1 ChIP-seq signal (log(LB1/Input)) LADs discovered in wild-type (WT LADs) and R6/1 (R6/1 LADs) mice; and common (green),
wild-type (WT)-specific (WT spec. LADs, red), and R6/1-specific (R6/1 spec. LADs, blue) LADs identified by EDD (top, WT (N = 3), R6/1 (N = 3)). Black arrows highlight
WT-specific LADs not identified in R6/1 mice. Box plot of average size (log10(LAD size + 1)) for common, WT-specific, and R6/1-specific LADs (right). The bottom and
top of the boxes are the first and third quartiles, and the line within represents the median. The whiskers denote the interval within 1.5 times the interquartile range
(IQR) from the median.
D Lamin B1 enrichment in common, wild-type (WT, N = 3)-specific (spec), and R6/1 (N = 3)-specific LADs (log10(LB1/Input reads + 1) in hippocampus (Hipp; left). Bar
graphs of significant (Benjamini’s adjusted P-value < 0.05) Biological Processes terms from DAVID for genes within common and WT-specific LADs (right). Gene-term
enrichment was estimated by DAVID using a modified Fisher’s exact test and Benjamini’s multiple correction test. Bars represent the –log10 (Benjamini’s adjusted P-
value). Exact P values are reported in Appendix Table S3.
E Representative immunoblot showing lamin B1 levels in the nucleoplasm (Nucleop) and chromatin (Chrom) in the hippocampus of 30-week-old wild-type (WT, N = 7)
and R6/1 (N = 7) mice. TBP, TATA-binding protein.
Source data are available online for this figure.
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from HD patients as, after sample processing, the number of nuclei
remaining was very low. In addition, when these nuclei were
analyzed, they did not present differences in comparison with the
nuclei from non-affected individuals. In contrast, the analysis of
lamin B1 levels by immunohistochemistry in HD patient MSN nuclei
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Therefore, we speculate that nuclear abnormalities potentiate MSN
loss after processing of the tissue, probably due to repeated centrifu-
gation, besides the neurodegenerative process itself. This could
result in the evaluation of those MSNs with a healthier nuclear
envelope (including “normal” lamin B1 levels) and not all the MSNs
remaining in the tissue. Indeed, immunohistochemistry analyses
confirmed an increase in lamin B1 levels in striatal neuronal nuclei
from VS III-IV HD patients in comparison with control individuals.
Altogether, our data support the idea of a cell-type-dependent
increase in lamin B1 levels, specifically in those neurons preferen-
tially affected in HD.
Our results show that increased lamin B1 levels correlate with
altered nuclear morphology in the R6/1 mice brain-specific neurons.
In fact, we show that the overexpression of lamin B1 in striatal
cultured neurons alters nuclear morphology. In agreement with our
results: (i) Nuclear morphology alterations in autosomal dominant
leukodystrophy brain cells have been related to increased lamin B1
levels (Ferrera et al, 2014), and (ii) by using lamin B1 as a marker,
nuclear envelope abnormalities have been shown in the brain of HD
patients and mouse models (Gasset-Rosa et al, 2017). Furthermore,
decreased levels of lamin B1 also result in nuclear morphology alter-
ations in AD (Frost et al, 2016) and PD (Liu et al, 2012) neurons
suggesting that proper lamin B1 levels are necessary to maintain a
correct neuronal nucleus morphology. In addition, nucleocytoplas-
mic transport was altered in those nuclei with increased lamin B1
levels in accordance with previous literature showing a link
between alterations in lamins and nuclear dysfunction. For instance,
in Hutchinson–Gilford progeria syndrome, the mutated form of A-
type lamin induces nucleocytoplasmic transport dysregulation by
inhibiting the nuclear localization of Ubc9 and disrupting the nucle-
ocytoplasmic Ran gradient, necessary for active transport (Kelley
et al, 2011). In addition, cells expressing progerin presented
perturbed passive and active transport toward and from the nucleus
(Ferri et al, 2017). Similarly, increased levels of lamin B1 affect
◀ Figure 8. Hippocampal chromatin accessibility and gene expression analysis in R6/1 mice hippocampus.
A Scheme showing major steps of ATAC-seq technique.
B UCSC genome browser capture of wild-type (WT, N = 3) and R6/1 (N = 3) mice hippocampus ATAC-seq data, hippocampal H3K9ac, and unchanged, closed in R6/1,
and open in R6/1 accessible detected regions (left) in Tuba1α, Gabra2α, and Dlx2 gene locus. Arrows in blue (closed in R6/1) and red (open in R6/1) indicate differential
accessible regions. Bar graphs of significant (Benjamini’s adjusted P-value < 0.05) Biological Processes terms from DAVID for genes associated with decreased (right
top) or increased (right bottom) chromatin accessibility regions. Gene-term enrichment estimated by DAVID using a modified Fisher’s exact test and Benjamini’s
multiple correction test. Bars represent the –log10 (Benjamini’s adjusted P-value). Exact P values are reported in Appendix Table S3.
C Box plots showing average gene expression (log10(FPKMs + 1) for genes up- or down-regulated (adjusted P-value < 0.001, |FC|>2) in R6/1 (N = 9) versus WT (N = 9)
mice (left). The bottom and top of the boxes are the first and third quartiles, and the line within represents the median. The whiskers denote the interval within 1.5
times the interquartile range (IQR) from the median. Heat map showing expression profile (log10 (FPKMs + 1)) of genes up- or down-regulated (adjusted P-
value < 0.001, |FC|>2, N = 9) in R6/1 mice (mid). Genes are ranked by the degree of expression. Numbers in color scale show the correspondence between gene
expression values and colors. Box plots showing average TSS chromatin accessibility (log10(ATAC reads + 1), N = 3) for genes up- or down-regulated (adjusted P-
value < 0.001, |FC|>2, N = 9) in R6/1 versus WT mice hippocampus (right). Exact P values are reported in Appendix Table S3. The bottom and top of the boxes are the
first and third quartiles, and the line within represents the median. The whiskers denote the interval within 1.5 times the interquartile range (IQR) from the median.
D Average gene expression (closed or open regions FPKMs/ unchanged regions FPKMs) for genes associated with differential accessible regions in R6/1 (N = 9) versus
WT (N = 9) mice (adjusted P-value < 0.05, N = 3). Each point corresponds to the value from an individual sample. Data are shown as the mean  SEM. *P < 0.05 as
compared with WT mice (two-tailed unpaired Student’s t-test). Exact P values are reported in Appendix Table S3.
Source data are available online for this figure.
▸Figure 9. Chromatin accessibility, gene expression, and lamin B1 chromatin-binding interconnexion.A Box plots of average expression (log10(FPKMs + 1)) for genes sublists 1-5 (lowest to highest expression) for wild-type (WT, N = 3) mice (left). Pie charts of gene
distribution among generated sublists (1-5) for all genes (middle) and genes in LADs (right) in WT mice. The bottom and top of the boxes are the first and third
quartiles, and the line within represents the median. The whiskers denote the interval within 1.5 times the interquartile range (IQR) from the median.
B Average gene expression (FPKMs) of genes found in common and wild-type (WT, N = 3)-specific LADs for WT (N = 9) and R6/1 (N = 9) mice. Each point corresponds
to the value from an individual sample. Data are shown as the mean  SEM. * P < 0.05 as compared to WT mice (two-tailed unpaired Student’s t-test). Exact P
values are reported in Appendix Table S3.
C Average chromatin accessibility (normalized read counts) of genes found in common and wild-type (WT, N = 3)-specific LADs for WT (N = 3) and R6/1 (N = 3) mice.
Each point corresponds to the value from an individual sample. Data are shown as the mean  SEM. The Wilcoxon–Mann–Whitney test was used for statistical
analysis. Exact P values are reported in Appendix Table S3.
D Venn diagram showing the total number of genes found in common and wild-type (WT)-specific LAD regions (left). Bar graph showing the number of up- and down-
regulated genes found in common and WT-specific LAD regions filtering only according to adjusted P-value (adjusted P-value < 0.001) or additionally with fold
change (adjusted P-value < 0.001, |FC| > 2) obtained from deseq2 differential expression analysis (see methods).
E UCSC genome browser capture of wild-type (WT, N = 3) and R6/1 (N = 3) mice hippocampus ATAC-seq data, lamin B1 ChIP-seq (log(Lb1 ChIP/Input)) for WT (N = 3)
and R6/1 (N = 3) mice hippocampus, hippocampal H3K9ac, CTCF, and H3K9me3 for WT mice hippocampus in Fos locus (left). Enhancer regions (E1-E5) are indicated
with arrows. Box plot of lamin B1 enrichment (log10(Lb1 ChIP/Input)) for regions with unchanged, decreased (closed in R6/1), and increased (opened in R6/1)
chromatin accessibility in R6/1 (N = 3) mice hippocampus. * P < 0.05 as compared to WT (N = 3) mice (the Wilcoxon–Mann–Whitney test). Exact P values are
reported in Appendix Table S3. The bottom and top of the boxes are the first and third quartiles, and the line within represents the median. The whiskers denote the
interval within 1.5 times the interquartile range (IQR) from the median.
Data information: In all graphs, bars represent the mean  SEM and each point corresponds to the value from an individual sample. Statistical analysis was performed
by one-way ANOVA followed by Bonferroni’s post hoc test except in (D) where data were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test. Exact P
values are reported in Appendix Table S3.
Source data are available online for this figure.
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nuclear export in HEK293 cells (Lin & Fu, 2009) and reduces nuclear
ion channel opening in fibroblasts from autosomal dominant
leukodystrophy patients (Ferrera et al, 2014). Furthermore, altered
lamin B levels and nucleocytoplasmic transport occur in AD (Efte-
kharzadeh et al, 2018) and PD (Chalovich et al, 2006) although
these alterations have never been linked between them. Altered
nucleocytoplasmic mRNA transport has been previously reported in
other HD models and has been indirectly associated with nucleo-
porins sequestration by mHtt inclusions (Gasset-Rosa et al, 2017;
Grima et al, 2017). In contrast, our immunohistochemical and
FANSI analyses indicated that increased lamin B1 and morphologi-
cal alterations occur in R6/1 mouse striatal and hippocampal
neuronal nuclei with and without the presence of mHtt inclusions.
These differences may be due to the use of different HD models, in
which forms of mHtt aggregation differ (Morton et al, 2000;
Hansson et al, 2001; Heng et al, 2010). Altogether, here we show
nuclear morphology and nucleocytoplasmic transport abnormalities
in HD brain that occur in a neuron type-dependent manner and that
are related, at least in part, to increased lamin B1 protein levels.
In order to study the consequences of lamin B1 alterations in
nuclear lamina heterochromatin organization, we generated, for the
first time, lamin B1 ChIP-seq data in mouse central nervous system
tissue and characterized hippocampal LADs which, as expected,
showed high homology with previous identified domains using
DamID (Peric-Hupkes et al, 2010). Our lamin B1 ChIP-seq data,
together with nuclear fractionation experiments, clearly showed a
perturbation in nuclear lamina heterochromatin organization and
lamin B1 chromatin binding. Interestingly, previous studies demon-
strated that lamin B1 overexpression in the central nervous system
leads to epigenetic alterations affecting the heterochromatin protein 1
β (HP1β) and methylated histone H3 (H3K9) as well as transcriptional
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that, the striatum of the R6/2 mouse model of HD shows important
alterations in H3K9me3 coverage (Lee et al, 2017) that, as we have
shown, is highly enriched in LADs. While the high extent of transcrip-
tional and chromatin accessibility alterations we have identified in R6/
1 mice hippocampus can be hardly explained exclusively by the subtle
alterations identified in lamin B1 ChIP-seq data, our results indicated
that regions with gained chromatin accessibility in our ATAC-seq data
showed a global decrease in the binding of lamin B1, correlative
increased expression, and were enriched in terms associated with cell
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neuronal cells (Merienne et al, 2019), suggesting that chromatin relax-
ation and consequent induction of gene expression could be, at least
in part, a result of the loss of lamin B1 chromatin binding. In accor-
dance with this, a previous study showed a general gain of chromatin
accessibility in HD T cells (Park et al, 2017), while our hippocampal
ATAC-seq data showed a bi-directionality in chromatin accessibility
changes, with a clear compaction of neuronal-associated regulatory
regions and increased chromatin relaxation in developmental related
ones. This is in agreement with a recent study demonstrating that HD
neuronal and glial cells are affected in opposite ways at transcriptional
level (Merienne et al, 2019). Our R6/1 hippocampal transcriptional
data showed a great overlap with previously generated data in addi-
tional HD models (Valor et al, 2013; Langfelder et al, 2016), and
according to a recent study, these common transcriptional signatures
present high homology with those found in knockouts for histone
acetyltransferases and methyltransferases (Hervas-Corpion et al,
2018). Being shown the interplay between lamin B1 protein levels and
H3K9me3, highly dependent on the activity of methyltransferases, it
can be speculated that nuclear lamina alterations identified in the
present work could lead to a reorganization of H3K9me3 coverage in
HD hippocampus. Altogether, our data suggest a new mechanism
contributing to the complex epigenetic landscape of HD (reviewed in
Francelle et al, 2017).
Finally, with the purpose of addressing the therapeutic relevance
of our findings, we used betulinic acid, which has the potential to
normalize lamin B1 protein levels (Li et al, 2013). We show a bene-
ficial effect in preventing HD cognitive dysfunction and, for the first
time, in normalizing lamin B1 protein levels in the brain in vivo.
Interestingly, we observed a functional recovery of hippocampal
memory-dependent tasks, which at the molecular level coincides
with a normalization of lamin B1 levels in the hippocampus of R6/1
mice, an improvement in nuclear morphology and function of CA1
neurons, and no effect on mHtt aggregates. The fact that nuclear
improvement occurred despite the presence of mHtt aggregates
supports a role of lamin B1 alterations in the nuclear dysfunction
previously observed in HD (Gasset-Rosa et al, 2017; Grima et al,
2017). In line with our results, cytotoxicity is reduced in primary
cortical neurons expressing mHtt after pharmacological restoration
of nucleocytoplasmic transport (Grima et al, 2017). Our results
strengthen the idea of a relationship between increased lamin B1
levels and alterations in nuclear morphology and function in HD, at
least in CA1 hippocampal neurons, as previously suggested in auto-
somal dominant leukodystrophy (Ferrera et al, 2014), which ulti-
mately contribute to the HD phenotype. In contrast, lamin B1 levels
were not normalized in the striatum after betulinic acid treatment
although partial amelioration of motor learning dysfunction was
observed in R6/1 mice. Since cortical pyramidal neuronal project to
the striatum and betulinic acid normalized lamin B1 levels in the
cortex, we speculate that the improvement of cortical neuronal func-
tion could have beneficial effects on MSNs, reflected by the preven-
tion in the decrease in DARPP-32 protein levels, a hallmark of HD
(Bibb et al, 2000), and consequently, motor performance is partially
improved. In addition to the regulation of lamin B1 levels, betulinic
acid has been shown to exert beneficial effects in affected brain
through the regulation of cAMP, cGMP, and BDNF levels (Kaundal
et al, 2018), long-term potentiation (Navabi et al, 2018), oxidative
stress (Lu et al, 2011), or inflammation (Li et al, 2018), which may
contribute to the improvement of R6/1 mice cognitive behavior.
Therefore, our results open a new therapeutic window not only for
HD, but also for autosomal dominant leukodystrophy, for which no
effective treatment is available yet (Padiath, 2019).
Altogether, our findings suggest a relationship between increased
lamin B1 levels and nuclear morphological and functional alter-
ations in specific HD brain neurons, which may contribute to the
pathophysiology of the disease and could have promising applica-
tions at the therapeutic level.
Materials and Methods
HD mouse model
Male R6/1 transgenic mice (B6CBA background) expressing the exon
1 of mHtt with 145 CAG repeats and their wild-type littermate
◀ Figure 10. Chronic treatment with betulinic acid improves cognitive function and modulates lamin B1 levels in the hippocampus and cortex of R6/1 mice.
A Timeline of the behavioral, biochemical, and histopathological analyses performed in wild-type (WT) and R6/1 mice to assess the effect of betulinic acid (BA)
administration. w, weeks; AR, accelerating rotarod.
B, C Graphs show the percentage of time exploring each object with respect to the total exploration time in the (B) NOLT and (C) NORT, 5 weeks after treatment (Veh,
vehicle; BA, betulinic acid; WT, wild-type). ****P < 0.0001 compared with the corresponding old location/object. WT veh N = 13; R6/1 veh N = 10; R6/1 + BA
N = 10.
D Accelerating rotarod was assessed after 7 weeks of treatment. **P < 0.01 and ***P < 0.001 compared with vehicle-treated wild-type (WT) mice; #P < 0.05
compared with vehicle-treated R6/1 mice. WT veh N = 13; R6/1 veh N = 9; R6/1 + BA N = 9.
E Lamin B1 levels were analyzed by Western blot in the striatum (WT veh N = 10; R6/1 veh N = 6; R6/1 + BA N = 7), hippocampus (WT veh N = 12; R6/1 veh N = 8;
R6/1 + BA N = 7), and cortex (WT veh N = 11; R6/1 veh N = 6; R6/1 + BA N = 7) after 12 weeks of treatment. *P < 0.05, **P < 0.05 compared with vehicle-treated
wild-type (WT) mice and #P < 0.05 compared with vehicle-treated R6/1 mice. Representative immunoblots of lamin B1 and α-tubulin (as loading control) for each
treatment group are shown.
F Lamin B1 intensity and nuclear morphology were analyzed by FANSI in hippocampal CA1 neuronal nuclei from wild-type (WT) and R6/1 mice after 12 weeks of
treatment. *P < 0.05 compared with vehicle-treated WT mice. *P < 0.05 as compared to vehicle-treated WT mice. Lamin B1 intensity: WT veh N = 6; R6/1 veh
N = 5; R6/1 + BA N = 4; lamin B1 circularity: WT veh N = 6; R6/1 veh N = 5; R6/1 + BA N = 5.
G Nuclear permeability was analyzed by FRAP in hippocampal CA1 neuronal nuclei after 12 weeks of treatment. *P < 0.05 compared with vehicle-treated wild-type
(WT) mice. WT veh N = 4; R6/1 veh N = 5; R6/1 + BA N = 6.
Data information: In all graphs, bars represent the mean  SEM and each point corresponds to the value from an individual sample. Statistical analysis was performed
by one-way ANOVA followed by Bonferroni’s post hoc test except in (D) where data were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test. Exact P
values are reported in Appendix Table S3.
Source data are available online for this figure.
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controls were used for this study. Mouse genotyping and CAG
repeat length determination were performed as previously described
(Mangiarini et al, 1996). All mice were housed together in numerical
birth order in groups of mixed genotypes, and male littermates were
randomly assigned to experimental groups. Data were recorded for
analysis by microchip mouse number, and experiments were
conducted in a blind-coded manner respect to genotype. The
animals were housed with access to food and water ad libitum in a
colony room kept at 19–22°C and 40–60% humidity, under a 12:12-
h light/dark cycle. All procedures were carried out in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and approved by the local animal care commit-
tee of the Universitat de Barcelona, following European (2010/63/
UE) and Spanish (RD53/2013) regulations for the care and use of
laboratory animals.
Post-mortem human brain tissue
Frozen samples (putamen, hippocampus, and frontal cortex) and
brain slices (5-μm-thick sections paraffin-embedded mounted in
glass slides) from HD patients and control individuals were obtained
from the Neurological Tissue Bank of the Biobank-Hospital Clı́nic-
Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS;
Barcelona, Catalonia, Spain) following the guidelines and approval
of the local ethics committee (Hospital Clı́nic of Barcelona’s Clinical
Research Ethics Committee). Informed consent was obtained from
all subjects, and experiments were performed conformed the princi-
ples set out in the WMA Declaration of Helsinki and Department of
Health and Human Services Belmont Report. Details on the sex, age,
CAG repeat length, Vonsattel grade, and post-mortem delay are
found in Appendix Table S1.
Pharmacological treatment
R6/1 mice were treated (from 8 to 20 weeks of age) with vehicle
(90% water, 10% polysorbate 80) or betulinic acid (50 mg/kg; Sigma-
Aldrich, #855057) administered by oral gavage, 3 days/week. Wild-
type mice were treated with vehicle. Animal weight was recorded
each day of treatment. Days in which treatment and tests were coinci-
dent, mice were allowed to recover during 1 h before starting a task.
Mice were sacrificed by cervical dislocation 1 h after the last dose.
Half of the brain was fixed in 4% PFA for immunostaining analysis,
and the striatum, hippocampus, and cortex from the other half were
rapidly removed and stored at –80°C until analysis.
Behavioral assessment
Spatial and recognition memory tests
NOLT and NORT were used to analyze hippocampal-dependent
spatial long term and recognition memory, respectively, in wild-type
and R6/1 mice at 13 weeks of age as previously described (Garcia-
Forn et al, 2018). In each of the tests, the object preference was
measured as the time exploring each object × 100/time exploring
both objects. The arena and the objects were rigorously cleaned
between animal trials to avoid odors. Animals were tracked with
SMART Junior software from Panlab (Barcelona, Spain). Days, in
which treatment and tests were coincident, the mice were allowed
to recover for 1 h after the treatment before starting any task.
Accelerating rotarod
For the assessment of motor learning dependent on the corticostriatal
connectivity, we performed the accelerating rotarod test at 15 weeks
of age. The protocol was performed as previously described (Garcia-
Forn et al, 2018) The final performance was calculated as the mean
latency to fall during the 3 last trials of each day. Days, in which
treatment and tests were coincident, the mice were allowed to
recover for 1 h after the treatment before starting any task.
Knock-in striatal cell line
Conditionally immortalized wild-type huntingtin knock-in striatal
cells, STHdhQ7/Q7, were grown as previously described (Trettel et al,
2000) on 12-mm round glass coverslips and were transfected at
50% of confluence. PKCδ siRNA (ON-TARGETplus Mouse Prkcd
siRNA-SMART Pool, Dharmacon) was used for PKCδ silencing, and
a scramble siRNA (Silencer® Select Negative Control No. 1 siRNA,
Catalog Number 4390844) was used as a control. To overexpress
mHtt, an exon 1 Htt plasmid expressing 94 CAG repeats tagged with
the CFP (Ortega et al, 2010) was used. Exon 1 mHtt plasmid
(0.5 µg) was transfected at the same time as the siRNAs (10 pmol)
using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA), and cells
were incubated for 24 h.
Striatal primary cultures
Striatal primary cultures were obtained and maintained as previ-
ously described (Gratacos et al, 2001) and grown on 12-mm round
glass coverslips. At 9 days in vitro, they were transfected with a
plasmid containing lamin B1 (mApple-lamin B1-10) or with a plas-
mid containing mApple-C1 as control. Both plasmids were a gift
from Michael Davidson (Addgene plasmid, #54917 and #54631,
respectively). Transfection was performed in 24-well plates using
2 µg of DNA and 1:2 TransFectinTM Lipid Reagent (Bio-Rad) follow-
ing the manufacturer’s instructions. After 45 min, medium was
exchanged for 50% of fresh medium and 50% of neuronal condi-
tioned medium. Cells were fixed 24 h post-transfection.
Protein extraction and Western blot analyses
Animals were killed at different ages by cervical dislocation. Brains
were quickly removed, and the striata, hippocampi, and cortex were
dissected out and homogenized in lysis buffer. Protein extraction
from mouse and human brain tissue, and from cultured cells, and
Western blot analyses were performed as previously described
(Xifro et al, 2008; Saavedra et al, 2011). After incubation with
primary and the appropriated horseradish peroxidase-conjugated
secondary antibodies (Appendix Table S2), membranes were
washed with Tris-buffered saline containing 0.1% Tween 20.
Immunoreactive bands were finally visualized using the Western
Blotting Luminol Reagent (Santa Cruz Biotechnology, #sc-2048) and
quantified by a computer-assisted densitometer (Gel-Pro Analyzer,
version 4, Media Cybernetics).
Immunofluorescence
Mice perfusion, brain processing, and immunostaining were
performed as previously described (Rue et al, 2014). For human
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tissue, the first step was dewaxing and rehydrating the tissue by
performing a series of 5 min each: xylene (four times), absolute
ethanol (three times), alcohol 96% (three times), and distilled
water. The antigen retrieval was performed afterward by boiling the
sections in citrate buffer (10 mM sodium citrate, 0.05% Tween 20,
pH 6.0) in a microwave for 20 min. After this, the Dako Autostainer
Plus was used for a blocking step during 15 min at room tempera-
ture with a commercial wash buffer from Dako supplemented with
3% normal goat serum, three washes with phosphate-buffered
saline (PBS), and the incubation with the primary antibody in the
Dako Real TM antibody diluent (Agilent, #S202230-2) for 30 min.
After incubation with primary antibodies, sections were washed
with PBS and incubated overnight with corresponding secondary
antibodies (Appendix Table S2). Finally, sections were mounted
with DAPI Fluoromount-G (Thermo Fisher Scientific, #00-4959-52).
Negative controls were performed for each primary antibody, and
no signal was detected in this condition.
For immunocytochemistry, cells were washed with PBS and fixed
with 4% paraformaldehyde (PFA) in PBS for 10 min at room
temperature. To block the action of PFA, cells were incubated with
0.2 M glycine for 20 min at room temperature. After quenching with
50mM NH4Cl for 10 min, cells were permeabilized in blocking
buffer containing 1% BSA + 0.2% gelatin + 0.2% Triton X-100 in
PBS at room temperature. After blocking, cells were incubated with
rabbit anti-Lamin B1 (1:200; Abcam, Cambridge, UK) for 30 min at
room temperature. Next, cells were washed three consecutive times
with PBS and finally were incubated with Cy3 AffiniPure F(ab’)2
Fragment Goat Anti-Rabbit IgG, F(ab’)2 Fragment Specific (1:200,
Jackson ImmunoResearch, West Grove, PA, USA). Nuclei were
stained with DAPI Fluoromount.
Immunofluorescence imaging and analysis
Immunostained tissue sections and STHdhQ7/Q7 cells were examined
by using the Olympus BX60 (Olympus, Tokyo, Japan) epifluores-
cence microscope coupled to an Orca-ER cooled CCD camera
(Hamamatsu Photonics, Hamamatsu, Japan) or the Leica TCS SP5
laser scanning confocal microscope (Leica Microsystems Heidelberg
GmbH, Manheim, Germany) with Argon and HeNe lasers coupled to
a Leica DMI6000 inverted microscope at different magnifications
(from 10× to 63×). Striatal cultured neurons, striatal olig-2-positive
cells, and putamen z-stacks images were obtained with a Zeiss LSM
880 (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA) confocal
microscope using the ZEN acquisition software. Confocal images
were taken as stacks differed in 0.5 μm (for mouse brain tissue),
0.3 μm (for human brain tissue), or 0.6 µm (for striatal primary
neurons) in Z-axis with an HCX PL APO lambda blue 63× numerical
aperture objective and standard pinhole (1 Airy disk), and their
reconstruction was performed using ImageJ software (NIH,
Bethesda, USA).
For morphological analysis in tissue sections, a Z-projection of
confocal stack images was generated and nuclear segmentation was
performed using default parameters of StarDist ImageJ plugin (Sch-
midt et al, 2018). A minimum of 400 (for mouse striatal sections) or
40 (for human putamen sections) nuclei were detected and
computed for posterior morphological analysis. The morphological
parameters of resulting segmented nuclei were analyzed using
MorphoLibJ ImageJ plugin (Legland et al, 2016). Cultured cell nuclei
were analyzed using the ROI manager from ImageJ (an average of
20 and 12 nuclei per condition and culture were analyzed for
STHdhQ7/Q7 cells and striatal primary neurons, respectively).
Immunohistochemistry for mHtt aggregates detection
Coronal sections (30 µm) of the whole brain were obtained as
described above. Detection of mHtt aggregates was performed as
previously described (Garcia-Forn et al, 2018) by using the anti-
EM48 antibody. EM48 staining was examined in eight slices per
animal separated by 240 µm (covering the entire striatum or CA1
hippocampal region) by using the Computer-Assisted Stereology
Toolbox (CAST) software (Olympus Danmark A/S, Ballerup,
Denmark). Images were analyzed using CellProfiler Analyst soft-
ware.
FANSI
FANSI was the result of combining nuclear purification and
immunostaining (Benito et al, 2015) with ImageStream imaging flow
cytometer technology (Barteneva & Vorobjev, 2016) (Luminex
Corporation).
Nuclear purification and immunostaining
Frozen tissue was homogenized in low sucrose buffer (LSB; 0.32 M
sucrose, 5 mM CaCl2, 5 mM Mg(Ac)2, 0.1 mM EDTA, 50 mM
HEPES pH 8.0, 1 mM DTT, 0.1% Triton X-100) and fixed in 1%
formaldehyde for 10 min at room temperature in a rotating wheel.
Formaldehyde was quenched with 125 mM glycine incubation
during 5 min at room temperature in the rotating wheel. Tissue
homogenate was collected by centrifugation, resuspended in LSB,
and mechanically homogenized. After that, the homogenized solu-
tion was layered on the top of a high sucrose buffer (1 M sucrose,
3 mM Mg(Ac)2, 10 mM HEPES, pH 8.0, 1 mM DTT) and centrifuged
at 4°C to recover the nuclei. These were then resuspended in PBTB
(PBS, 5% BSA, 0.1% Tween-20) containing the antibodies and 3%
NHS, and incubated in a rotating wheel at 4°C during 30 min. After
that, samples were washed twice with PBTB plus 3% NHS and
stained with corresponding secondary antibodies in PBTB plus 3%
NHS at 4°C during 15 min. Nuclei were then washed, stained with
Hoechst 33258 (1:10,000; Thermo Fisher Scientific, #H3569), and
directly processed for Imaging flow cytometry.
Imaging flow cytometry (ImageStream)
Purified nuclei were resuspended in 100 µl and filtered using cells
strainers of 50 µm pore size (Sysmex Partec, Kobe, Japan) and poste-
riorly sorted and imaged using a 60× objective at a maximum speed
of 600 nuclei/s depending on the sample concentration. For each
replicate, a minimum of 10,000 nuclei were recorded. Fluorescent
minus one controls were used to evaluate the specificity of the
defined populations by individually removing primary but not
secondary antibodies (Appendix Fig S13A–F). Recorded files were
processed and analyzed by the IDEAS Software provided by the
ImageStream machine’s manufacturers (Luminex, Austin, USA) after
cross-channel signal compensation. After selecting individual nuclei
(singlets, only focused acquired images were used for posterior analy-
sis) (Appendix Fig S13F and G), lamin B1-positive nuclei were
selected for posterior analysis (Appendix Fig S7I) and screened
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according to their Ctip2 and Prox1 signal and the specific neuronal
nuclear marker NeuN. For hippocampal samples, CA1 nuclei were
classified as Ctip2+/Prox1− and DG ones as Ctip2+/Prox1+ (Bagri et al,
2002; Arlotta et al, 2005). For striatum and putamen, nuclei were
classified as MSNs (NeuN+/Ctip2+) (Herculano-Houzel & Lent, 2005;
Arlotta et al, 2008), interneurons (NeuN+/Ctip2−), or glia (NeuN−/
Ctip2−). All the features analyzed (mean intensity, circularity, and
mean area) were performed using these selected populations.
FRAP in isolated nuclei
Striatal nuclei were isolated as previously described (Alvarez-Periel
et al, 2018) and then incubated for 30 min at 4°C with the corre-
sponding primary and secondary antibodies (Appendix Table S2).
Nuclei were maintained in LSB until analysis. To perform conven-
tional single-photon FRAP experiments, nuclei were incubated with
a solution of 20 kDa FITC-dextran (0.3mg/ml; Sigma-Aldrich,
#FD20) and seeded in glass-bottomed chambers and covered with a
cover slip. Striatal MSN nuclei (Ctip2+/NeuN+) and hippocampal
CA1 (Ctip2+/Prox1−) and DG (Ctip2+/Prox1+) nuclei were manually
selected. Each FRAP experiment started with 5 pre-bleach image
scans, followed by 8 bleach pulses of 156 ms each on a spot with a
diameter of 2.5 µm in the center of the nucleus. At the post-bleach
period, a series of 100 single section images were collected at 156-
ms intervals (Appendix Fig S14). A total of 113 images were
acquired for each nucleus, and an average of 25 nuclei were
analyzed for each animal. Image size was 256 × 56 pixels, and the
pixel width was 120 × 60 nm. For imaging, the laser power was
attenuated to 3% of the bleach intensity. FRAP experiments were
performed on a Leica TCS SP5 laser scanning confocal spectral
microscope (Leica Microsystems, Heidelberg, Germany) equipped
with Argon laser and Leica DMI6000 inverted microscope. Images
were acquired using a 63×, 1.4 NA oil immersion objective lens,
and 1.5 Airy units as pinhole. Image processing was performed
using LAS AF Lite Software (Leica Microsystems, Heidelberg,
Germany). For each image, the fluorescence in the bleached region
was normalized for the fluorescence of the background and the
percentage of the initial fluorescence was calculated for each time
point. FRAP recovery curves were represented (Appendix Fig S9)
following the formula % fluorescence¼ ROItBGt ∗ROItoBGto
 
∗100, where ROIt
is the intensity in the selected ROI at time point t, BGt is the inten-
sity in the background at time point t, ROIt0 is the intensity in the
selected ROI at time 0, and BGt0 is the intensity in the background
at time 0. Data were analyzed using GraphPad Prism Software (San
Diego, USA).
Nuclear fractionation
Nuclear fractionation from hippocampus of 30-week-old wild-type and
R6/1 mice was performed using a Subcellular Protein Fractionation Kit
for Tissues (Thermo Fisher Scientific, #87790) following manufac-
turer’s instructions. Chromatin-bound and nuclear soluble fractions
were obtained and examined by Western blot as described above.
RNA-seq
RNA-seq data were generated from 30-week-old wild-type and R6/1
mice hippocampal tissue. RNA was isolated from 9 independent
biological replicates for each genotype using the RNeasy Plus Kit
(Qiagen, #74136) according to the manufacturer’s instructions.
Quality assessment was performed using Bioanalyser eukaryotic
total RNA nano series II chip (Agilent, #5067-1511), and all samples
achieved a RNA integration number (RIN) between 9 and 10.
Libraries were prepared from 9 biological replicates of each condi-
tion using the TruSeq Stranded mRNA Library Prep Kit (Illumina,
#20020594) following manufacturer’s instructions and sequenced
using the HiSeq 2500 sequencing platform (Illumina, San Diego,
USA).
ChIP-seq
Lamin B1 ChIP-seq was performed as previously described (Sadaie
et al, 2013) by using 30-week-old wild-type and R6/1 mice
hippocampal tissue. Briefly, for each biological replicate, hippocam-
pus from 5 mice was pooled together, homogenized in PBS supple-
mented with proteinase inhibitors (Sigma, #13317600), and
posteriorly cross-linked with formaldehyde 1% for 15 min at room
temperature. Cross-linking reaction was stopped by a 5 min of incu-
bation with 2 M glycine, and the cross-linked material was washed
3 times with ice-cold PBS. Cells were lysed using cell lysis buffer
(10 mM HEPES pH 8, 85 mM KCl, 0.5% NP-40), and nuclei were
extracted using nucleus extraction buffer (0.5% SDS, 10 mM EDTA
pH 8, 50 mM Tris–HCl pH 8). Purified nuclear fraction was
subjected to sonication using Bioruptor Pico (Diagenode, Belgium)
to obtain DNA fragments of 200–500 bp. Sonicated chromatin was
incubated overnight at 4°C with anti-rabbit magnetic Dynabeads
(Thermo Fisher Scientific, #11203D) pre-complexed with 10 µg of
rabbit anti-lamin B1 antibody. After 6 washes with RIPA buffer
(20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium
pyrophosphate, 1mM b-glycerophosphate, 1 mM Na3VO), chro-
matin was eluted and de-cross-linked by overnight incubation at
65°C, followed by a 30 min of RNase (Ambion, #AM2271) and 2 h
of proteinase K (Thermo Fisher Scientific, #AM2548) treatments.
DNA purification was carried out with MinElute PCR Purification Kit
(Qiagen, #28006), and libraries were prepared using the NEBNext
Ultra II DNA Library Prep Kit from Illumina (New England Biolabs,
#37645) according to the manufacturer’s instructions. DNA size
selection was performed after PCR amplification using E-Gel Precast
Agarose Electrophoresis System (Invitrogen, #A42100). Samples
were sequenced single end using 50-bp reads on the HiSeq 2500 and
HiSeq 4000 platforms (Illumina, San Diego, USA).
ATAC-seq
ATAC-seq experiments were performed as previously described
(Buenrostro et al, 2013), with slight modifications, in 3 independent
biological replicates using hippocampal tissue from 25-week-old
wild-type and R6/1 mice. Briefly, a frozen mouse hippocampus for
each biological replicate was pulverized using a grinder and pestle
settle on dry ice, and tissue powder was lysed in LB1 buffer (1M
HEPES pH 7.5, 5 M NaCl, 0.5 M EDTA pH 8.0, 50% glycerol, 10%
NP-40, 10% Triton X-100) for nuclear isolation. Approximately
50,000 nuclei were used for the transposition reaction using hyper-
active Tn5 transposase (Illumina Cat, #FC-121-1030) followed by 13
cycles of PCR amplification. “Nucleosome free” and “mono-
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nucleosome fragments” were obtained by size selection of DNA
fragments between 170 bp and 400 bp using SPRIselect beads
(Beckman Coulter, #B23319) before single-end sequencing to gener-
ate 50-bp reads on the HiSeq 4000 platform (Illumina, San Diego,
USA).
RNA-seq, ChIP-seq, and ATAC-seq data analysis
ChIP-seq samples were mapped against the mm9 mouse genome
assembly using Bowtie with the option –m 1 to discard those reads
that could not be uniquely mapped to just one region (Langmead
et al, 2009). We ran the EDD tool (parameters: GAP = 5 and BIN
SIZE = 37) to identify LADs on our ChIP-seq samples (Lund et al,
2014). Triplicates of each condition were pooled together, once a
high degree of similarity in the set of reported LADs and target genes
was confirmed among replicates. The UCSC genome browser was
used to generate the screenshots of each group of experiments along
the manuscript (Kent et al, 2002). The RNA-seq samples were
mapped against the mm9 mouse genome assembly using TopHat
(Trapnell et al, 2009) with the option –g 1 to discard those reads
that could not be uniquely mapped in just one region. DESeq2 (Love
et al, 2014) was run over nine replicates of each genotype to quan-
tify the expression of every annotated transcript using the RefSeq
catalog of exons and to identify each set of differentially expressed
genes. ATAC-seq samples were mapped against the mm9 mouse
genome assembly using Bowtie with the option –m 1 to discard
those reads that could not be uniquely mapped to just one region,
and with the option –X 2000 to define the maximum insert size for
paired-end alignment (Langmead et al, 2009). Mitochondrial reads
were removed from each resulting map, and down-sampling was
applied to obtain the same number of mapped fragments per
sample. Correlation between biological replicates in terms of peaks
was assessed to ensure high reproducibility before pooling each set
of triplicates. MACS was run with the default parameters but with
the shift size adjusted to 100 bp to perform peak calling (Zhang
et al, 2008). The genome distribution of each set of peaks was calcu-
lated by counting the number of peaks fitted on each class of region
according to RefSeq annotations (O’Leary et al, 2016). Distal region
is the region within 2.5 Kbp and 0.5 Kbp upstream of the transcrip-
tion start site (TSS). Proximal region is the region within 0.5 Kbp
upstream of the TSS. UTR, untranslated region; CDS, protein-coding
sequence; intronic regions, introns; and the rest of the genome,
intergenic. Peaks that overlapped with more than one genomic
feature were proportionally counted the same number of times. For
the generation of metaprofiles, seqMINER tool (Ye et al, 2011) was
used in combination with ggplot2 package from R (https://ggplot2.
tidyverse.org/) using an in-house script.
Differential chromatin accessibility
Integrated analysis of ATAC-seq data was performed using the open
Galaxy platform (https://usegalaxy.org/). A list of high confident
peaks identified with MACS2 for each genotype was generated by
selecting peaks found in at least 2 different replicates. For differential
accessible region identification, edgeR galaxy tool was used with a
merge of all high confident peaks identified in both genotypes apply-
ing the TMM method implemented in edgeR for normalization and
dispersion calculation of the different biological samples. The results
were further filtered based on FDR < 0.05. Peaks were annotated to
the closest TSS using Homer tool integrated in Galaxy platform.
Motif analysis
For motif analysis, the Meme-ChIP suite (version 4.12.0) tool (Bai-
ley et al, 2009) was used in differential enrichment mode together
with Hocomoco (version 11 FULL) human and mouse PWMs. As
input, 600-bp regions surrounding the summit of differential accessi-
ble peaks were used for motif discovery (using relaxed regions as
control for compacted regions and vice-versa) and only motifs
centrally enriched were considered.
Gene ontology
For functional enrichments in biological processes (BP), DAVID
(Huang et al, 2009) tool was used by providing closest genes ID
obtained by Homer when using differentially accessible regions,
with subsets of genes identified as differentially expressed or with
genes located in LAD-identified regions. Terms with Benjamini’s
adjusted P-value < 0.05 were selected for bar graph representations.
Data visualization
UCSC genome browser (Kent et al, 2002) was used for genome-wide
visualization of ChIP-seq and ATAC-seq data.
Statistics
Sample size was determined by using the power analysis method:
0.05 alpha value, 1 estimated sigma value, and 75% of power
The paper explained
Problem
Lamins, the major structural proteins within the nuclear lamina, are
crucial for the functionality of the nucleus. Our previous results
showed that lamin B levels are increased in a brain region-dependent
manner in Huntington’s disease (HD). However, it is not known
whether this alteration has consequences for nuclear function of cells
expressing mutant huntingtin and plays a role in HD pathophysiology.
Results
Lamins levels were analyzed in the cortex, striatum, and hippocampus
of the R6/1 mouse model of HD and HD patients. We observed a brain
region and age-dependent increase in lamin B1 levels. Through fluores-
cence-activated nuclear suspension imaging, we determined that lamin
B1 levels are increased in specific neuronal populations, which is corre-
lated with alterations in nuclear morphology and nucleocytoplasmic
transport disruption as assessed by fluorescence recovery after photo-
bleaching. In addition, ChIP-seq analysis in hippocampal nuclei from
R6/1 mouse showed a partial unstructuring of lamin B1-associated
domains and changes in chromatin accessibility (assessed by ATAC-seq),
which correlates with transcriptional dysregulation determined by
RNA-seq. In support of a significant role of lamin B1 in HD pathology,
the administration of betulinic acid in R6/1 mouse partially restored
lamin B1 levels and attenuated both motor and cognitive dysfunction.
Impact
Our work highlights increased lamin B1 levels as a new pathogenic
mechanism for HD, providing a novel target for its intervention.
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detection. Such analysis was chosen as the result of previous behav-
ioral experiments in our laboratory. N values are given throughout
the manuscript in the figure legends. Grubb’s test was performed to
determine the significant outlier values with pre-established criteria.
All the results are expressed as the mean  SEM. Statistical tests
were performed using Student’s t-test for one grouping variable and
the one or two-way ANOVA for multi-component variables,
followed by Bonferroni’s or Turkey’s post hoc test as indicated in
the figure legends. Linear regression analyses were performed using
R-squared. For non-parametric ChIP-seq and ATAC-seq data analy-
sis, the Wilcoxon–Mann–Whitney test was used as indicated in fig-
ure legend. Additional statistical analysis for ChIP-seq, ATAC-seq,
and RNA-seq data is indicated in their respective sequencing analy-
sis section. A 95% confidence interval was used, and values with a
P < 0.05 were considered as statistically significant.
Data availability
Raw data and processed information of the ChIP-seq, ATAC-seq,
and RNA-seq experiments generated in this article were deposited in
the National Center for Biotechnology Information Gene Expression
Omnibus (NCBI GEO) (Barrett et al, 2013) repository under the
Accession Number GSE139884. Additionally, public datasets for
hippocampal H3K9me3 (GSM2460430, https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSM2460430) (Ding et al, 2017),
H3K9ac (GSM2415914, https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSM2415914) (Mews et al, 2017), and CTCF
(GSM2228526, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSM2228526) (Sams et al, 2016) ChIP-seq experiments were
retrieved for integrated data analysis.
Expanded View for this article is available online.
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